Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04051463 · ClinicalTrials.gov registry record · Phase 2
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
A Phase 2 study, sponsored by Price Vision Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT04051463: Completed Phase 2 study, sponsored by Price Vision Group.
NCT04051463 is a Phase 2 study that has completed, run by Price Vision Group. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04051463, a Phase 2 study, has completed, sponsored by Price Vision Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
Primary Outcome
Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline
Interventions
- DRUG Placebo
- DRUG Netarsudil Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
What the finished NCT04051463 record still lists
NCT04051463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04051463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04051463 about?
NCT04051463 is a clinical study titled "Rhopressa for Corneal Edema Associated With Fuchs Dystrophy". The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
What is the current status of trial NCT04051463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2019-08-05. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT04051463?
The interventions under investigation include: Placebo (DRUG), Netarsudil Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04051463?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04051463's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI